Personalis, Inc. to Current at Biomarkers 7 days On line 2021 | Enterprise
3 min readMENLO PARK, Calif.–(Company WIRE)–Might 17, 2021–
Personalis, Inc. (Nasdaq: PSNL), a chief in advanced genomics for most cancers, nowadays announced that the organization will present at Biomarkers Week On line 2021.
The presentation, titled “ImmunoID Next Platform® for in depth tumor immunogenomics and advanced biomarker discovery,” will explain the Personalis universal most cancers immunogenomics system, ImmunoID Future ™. Erin Newburn, MS, PhD, will present for Personalis. Dr. Newburn will supply an overview of the platform, which brings together extremely delicate, exome-scale DNA and RNA sequencing with highly developed analytics to give a multidimensional watch of the tumor and the tumor microenvironment (TME) from a solitary sample planning. Dr. Newburn will assessment a scenario research in a cohort of 51 late-phase melanoma clients that demonstrates how the integration of neoantigen load, HLA LOH, and Antigen Presentation Equipment (APM) mutational details shaped a composite biomarker that far more correctly predicted response to checkpoint blockade than other markers. On top of that, Dr. Newburn will spotlight our Following Liquid Biopsy™, an exome-wide liquid biopsy solution put together with ImmunoID Up coming, to additional examine important locations of tumor biology.
ImmunoID Subsequent is the very first platform to empower complete examination of both a tumor and its immune microenvironment from a single sample. The ImmunoID Following System can be employed to investigate the critical tumor- and immune-related regions of cancer biology, consolidating numerous oncology biomarker assays into one and maximizing the biological details that can be created from a cherished tumor specimen.
Personalis is a co-sponsor of Biomarkers 7 days and will have reps readily available to response thoughts about the company’s most cancers immunogenomics capabilities.
About Personalis, Inc.
Personalis, Inc. is a chief in populace sequencing and most cancers genomics, with a target on facts, scale, effectiveness, and quality. Personalis operates one of the biggest sequencing functions globally and is presently the sole sequencing company to the VA MVP. In oncology, Personalis is transforming the enhancement of upcoming-era therapies by providing a lot more extensive molecular info about each and every patient’s most cancers and immune response. The Personalis® ImmunoID Following System is built to adapt to the sophisticated and evolving knowing of most cancers, giving its biopharmaceutical prospects with details on all of the roughly 20,000 human genes, together with the immune system, from a single tissue and matched blood sample. The Personalis Scientific Laboratory is GxP aligned as properly as CLIA’88-licensed and CAP-accredited. For much more details, make sure you pay a visit to www.personalis.com and follow Personalis on Twitter ( @PersonalisInc ).
Forward-Wanting Statements
All statements in this press release that are not historical are “forward-wanting statements” inside of the that means of U.S. securities rules, like statements relating to attributes or positive aspects of the Personalis Up coming System, Personalis’ company prospects, management, plans, vision or progress, or other upcoming events. These types of forward-looking statements contain pitfalls and uncertainties, such as all those relevant to the COVID-19 pandemic, that could trigger precise outcomes to differ materially from any predicted outcomes or anticipations expressed or implied by these kinds of statements. Components that could materially influence real final results can be found in Personalis’ filings with the U.S. Securities and Trade Commission, which includes Personalis’ most latest studies on Types 8-K, 10-K and 10-Q, and incorporate people mentioned underneath the caption “Risk Things.” Personalis disclaims any obligation to update these types of ahead-searching statements.
Check out supply variation on businesswire.com:https://www.businesswire.com/news/residence/20210517005432/en/
Make contact with: Investor Relations Make contact with for Personalis:
Caroline Corner
415-202-5678Media Speak to for Personalis:
Jennifer Havlek
650-752-1300
Keyword: UNITED STATES NORTH America CALIFORNIA
Market Key phrase: ONCOLOGY Well being GENETICS Exploration SCIENCE PHARMACEUTICAL BIOTECHNOLOGY
Resource: Personalis, Inc.
Copyright Business Wire 2021.
PUB: 05/17/2021 08:01 AM/DISC: 05/17/2021 08:02 AM
Copyright Business Wire 2021.
